Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$10.15 USD
+0.36 (3.70%)
Updated May 31, 2024 04:00 PM ET
After-Market: $10.40 +0.25 (2.46%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PIRS 10.15 +0.36(3.70%)
Will PIRS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PIRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PIRS
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
PIRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for August 23rd
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
Other News for PIRS
PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Pieris Pharmaceuticals: Q1 Earnings Snapshot
Looking Into Pieris Pharmaceuticals's Recent Short Interest
Pieris Pharmaceuticals trading halted, news pending